Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Varca AC"'
Autor:
Chan WC; Department of Cancer Biology and the Linde Program in Cancer Chemical Biology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA., Liu X; Department of Cancer Biology and the Linde Program in Cancer Chemical Biology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA., Magin RS; Department of Cancer Biology and the Linde Program in Cancer Chemical Biology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA., Girardi NM; Department of Cancer Biology and the Linde Program in Cancer Chemical Biology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA., Ficarro SB; Department of Cancer Biology and the Linde Program in Cancer Chemical Biology, Dana-Farber Cancer Institute, Boston, MA, USA.; Blais Proteomics Center, Dana-Farber Cancer Institute, Boston, MA, USA.; Center for Emergent Drug Targets, Dana-Farber Cancer Institute, Boston, MA, USA., Hu W; Department of Cancer Biology and the Linde Program in Cancer Chemical Biology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA., Tarazona Guzman MI; Department of Cancer Biology and the Linde Program in Cancer Chemical Biology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA., Starnbach CA; Department of Cancer Biology and the Linde Program in Cancer Chemical Biology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA., Felix A; Department of Cancer Biology and the Linde Program in Cancer Chemical Biology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA., Adelmant G; Department of Cancer Biology and the Linde Program in Cancer Chemical Biology, Dana-Farber Cancer Institute, Boston, MA, USA.; Blais Proteomics Center, Dana-Farber Cancer Institute, Boston, MA, USA., Varca AC; Department of Cancer Biology and the Linde Program in Cancer Chemical Biology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA., Hu B; Department of Cancer Biology and the Linde Program in Cancer Chemical Biology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA., Bratt AS; Department of Cancer Biology and the Linde Program in Cancer Chemical Biology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA., DaSilva E; Department of Cancer Biology and the Linde Program in Cancer Chemical Biology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA., Schauer NJ; Department of Cancer Biology and the Linde Program in Cancer Chemical Biology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA., Jaen Maisonet I; Department of Cancer Biology and the Linde Program in Cancer Chemical Biology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA., Dolen EK; Department of Cancer Biology and the Linde Program in Cancer Chemical Biology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA., Ayala AX; Department of Cancer Biology and the Linde Program in Cancer Chemical Biology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA., Marto JA; Department of Cancer Biology and the Linde Program in Cancer Chemical Biology, Dana-Farber Cancer Institute, Boston, MA, USA. jarrod_marto@dfci.harvard.edu.; Blais Proteomics Center, Dana-Farber Cancer Institute, Boston, MA, USA. jarrod_marto@dfci.harvard.edu.; Center for Emergent Drug Targets, Dana-Farber Cancer Institute, Boston, MA, USA. jarrod_marto@dfci.harvard.edu.; Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA. jarrod_marto@dfci.harvard.edu., Buhrlage SJ; Department of Cancer Biology and the Linde Program in Cancer Chemical Biology, Dana-Farber Cancer Institute, Boston, MA, USA. saraj_buhrlage@dfci.harvard.edu.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA. saraj_buhrlage@dfci.harvard.edu.; Center for Emergent Drug Targets, Dana-Farber Cancer Institute, Boston, MA, USA. saraj_buhrlage@dfci.harvard.edu.; Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA. saraj_buhrlage@dfci.harvard.edu.
Publikováno v:
Nature communications [Nat Commun] 2023 Feb 08; Vol. 14 (1), pp. 686. Date of Electronic Publication: 2023 Feb 08.
Autor:
Varca AC; Department of Cancer Biology and the Linde Program in Cancer Chemical Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02115, USA., Casalena D; FAST Lab, Chemical Biology and Therapeutics, Novartis Institutes for BioMedical Research, Cambridge, MA 02139, USA., Chan WC; Department of Cancer Biology and the Linde Program in Cancer Chemical Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02115, USA; Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA; Blais Proteomics Center, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Hu B; Department of Cancer Biology and the Linde Program in Cancer Chemical Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02115, USA., Magin RS; Department of Cancer Biology and the Linde Program in Cancer Chemical Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02115, USA., Roberts RM; Department of Cancer Biology and the Linde Program in Cancer Chemical Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02115, USA., Liu X; Department of Cancer Biology and the Linde Program in Cancer Chemical Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02115, USA., Zhu H; Department of Cancer Biology and the Linde Program in Cancer Chemical Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA; Department of Oncologic Pathology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Blais Proteomics Center, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Seo HS; Department of Cancer Biology and the Linde Program in Cancer Chemical Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Dhe-Paganon S; Department of Cancer Biology and the Linde Program in Cancer Chemical Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Marto JA; Department of Cancer Biology and the Linde Program in Cancer Chemical Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA; Blais Proteomics Center, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Auld D; FAST Lab, Chemical Biology and Therapeutics, Novartis Institutes for BioMedical Research, Cambridge, MA 02139, USA., Buhrlage SJ; Department of Cancer Biology and the Linde Program in Cancer Chemical Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02115, USA. Electronic address: saraj_buhrlage@dfci.harvard.edu.
Publikováno v:
Cell chemical biology [Cell Chem Biol] 2021 Dec 16; Vol. 28 (12), pp. 1758-1771.e13. Date of Electronic Publication: 2021 Jun 14.
Autor:
Varca AC; Department of Cancer Biology and the Linde Program in Cancer Chemical Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02115, USA., Casalena D; FAST Lab, Chemical Biology and Therapeutics, Novartis Institutes for BioMedical Research, Cambridge, MA 02139, USA., Auld D; FAST Lab, Chemical Biology and Therapeutics, Novartis Institutes for BioMedical Research, Cambridge, MA 02139, USA., Buhrlage SJ; Department of Cancer Biology and the Linde Program in Cancer Chemical Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02115, USA.
Publikováno v:
STAR protocols [STAR Protoc] 2021 Oct 19; Vol. 2 (4), pp. 100896. Date of Electronic Publication: 2021 Oct 19 (Print Publication: 2021).
Autor:
Bushman JW; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02115, USA., Donovan KA; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02115, USA., Schauer NJ; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02115, USA., Liu X; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02115, USA., Hu W; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02115, USA., Varca AC; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02115, USA., Buhrlage SJ; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02115, USA., Fischer ES; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02115, USA. Electronic address: eric_fischer@dfci.harvard.edu.
Publikováno v:
Cell chemical biology [Cell Chem Biol] 2021 Jan 21; Vol. 28 (1), pp. 78-87.e3. Date of Electronic Publication: 2020 Oct 01.
Autor:
Roti G; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA.; Division of Hematology/Oncology, Boston Children's Hospital, Boston, MA.; Department of Medicine and Surgery, University of Parma, Italy., Qi J; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA., Kitara S; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA.; Division of Hematology/Oncology, Boston Children's Hospital, Boston, MA., Sanchez-Martin M; Institute of Cancer Genetics, Columbia University, New York, NY., Saur Conway A; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA.; Division of Hematology/Oncology, Boston Children's Hospital, Boston, MA., Varca AC; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA., Su A; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA.; Division of Hematology/Oncology, Boston Children's Hospital, Boston, MA., Wu L; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA., Kung AL; Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY., Ferrando AA; Institute of Cancer Genetics, Columbia University, New York, NY., Bradner JE; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA james.bradner@novartis.com.; Department of Medicine, Harvard Medical School, Boston, MA.; Novartis Institutes for Biomedical Research, Cambridge, MA., Stegmaier K; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA kimberly_stegmaier@dfci.harvard.edu.; Division of Hematology/Oncology, Boston Children's Hospital, Boston, MA.; Broad Institute, Cambridge, MA.
Publikováno v:
The Journal of experimental medicine [J Exp Med] 2018 Jan 02; Vol. 215 (1), pp. 197-216. Date of Electronic Publication: 2017 Nov 20.
Autor:
Yi JS; †Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, United States.; ‡Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, United States.; §Department of Pediatrics, Harvard Medical School, Boston, Massachusetts, United States., Federation AJ; †Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, United States., Qi J; †Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, United States., Dhe-Paganon S; ∥Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts, United States., Hadler M; ⊥Human Oncology and Pathogenesis Program, Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York, United States., Xu X; #Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts, United States., St Pierre R; †Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, United States., Varca AC; †Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, United States., Wu L; ○Shanghai ChemPartner Co. Ltd., 998 Hailei Road, Zhangjiang Hi-Tech Park, Pudong New Area, Shanghai, 201203, China., Marineau JJ; †Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, United States., Smith WB; †Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, United States., Souza A; †Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, United States., Chory EJ; †Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, United States., Armstrong SA; ⊥Human Oncology and Pathogenesis Program, Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York, United States., Bradner JE; †Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, United States.; ▽Department of Medicine, Harvard Medical School, Boston, Massachusetts, United States.
Publikováno v:
ACS chemical biology [ACS Chem Biol] 2015 Mar 20; Vol. 10 (3), pp. 667-74. Date of Electronic Publication: 2015 Jan 15.